SynthesisFrontiers in immunology2026
Meta-analysis of factors for osteonecrosis in systemic lupus erythematosus: integration of comprehensive literatures and multicenter databases.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteonecrosis (ON) is a prevalent and severe complication in patients with systemic lupus erythematosus (SLE). However, the etiology and mechanism of SLE-ON have not been fully elucidated. This study aims to investigate the factors related to SLE-ON and provide a basis for early prevention and control. Methods: A comprehensive search of relevant literatures was conducted from PubMed, Ovid Medline, Web of Science, Embase, Cochrane Library, CNKI, Wanfang Data, and VIP Information databases up to 31 October 2025. According to the inclusion and exclusion criteria, 3,051 studies were examined, and quality of each study was assessed using the Newcastle-Ottawa scale (NOS). Meta-analysis methods discussed the association of the factors related to SLE-ON. Results: A total of 64 studies were finally included in the meta-analysis. For clinical features, factors such as neuropsychiatric lupus (OR = 1.652), hyperlipidemia (OR = 1.358), oral ulcers (OR = 1.319), pleuritis (OR = 2.225), malar rash (OR = 1.311), vasculitis (OR = 2.638), serositis (OR = 1.514), hematologic involvement (OR = 1.190), Reynaud's phenomenon (OR = 1.604), thrombophlebitis (OR = 1.856), and arthritis (OR = 1.256) were positively related to SLE-ON risk. For laboratory features, proteinuria (OR = 1.635), antiphospholipid antibody (OR = 1.450), elevated ESR (OR = 1.623), leukopenia (OR = 1.317), and ACL (OR = 1.657) were positively related to SLE-ON risk as well. Interestingly, the anti-SSA antibody (OR = 0.805) and anti-SSB antibody (OR = 0.764) were negatively related to SLE-ON susceptibility. Usage of cyclophosphamide (OR = 1.869) and steroid pulse therapy (OR = 1.829) was positively correlated with occurrence of SLE-ON. Furthermore, younger age (SMD=-0.175) and the age at onset (SMD=-0.426) significantly related to developing of SLE-ON. Conclusion: A total of 32 factors including clinical, laboratory features, drug usage, and basic information in SLE patients were related to SLE complicated with osteonecrosis. Of note, the association between cyclophosphamide/steroid pulse therapy and SLE-ON risk may be confounded by underlying disease severity, so these results should be interpreted cautiously. Targeted monitoring and intervention of these modifiable risk factors, especially optimized steroid pulse therapy and cyclophosphamide use and early osteoporosis screening, combined with risk stratification based on anti-SSA/SSB antibody status, may help reduce SLE-ON risk and improve clinical management of SLE patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.